Blood-based protein biomarkers in bladder urothelial tumors

López-Cortés, Rubén; Gómez, Benito Blanco; Vázquez‐Estévez, Sergio; Núñez, Cristina

doi:10.1016/j.jprot.2021.104329

Cited by 12 publications

(13 citation statements)

References 222 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor biomarkers are mainly used in clinical practice to detect primary tumors and screen for risk-high groups, contributing to the prognosis and treatment outcome of patients ( López-Cortés et al, 2021 ). In recent years, some BCa-related tumor markers have been used in the clinic to help detect clinically occult cancer, such as bladder tumor antigen and epithelial cells marker ( Stefan-van Staden et al, 2020 ; Gouin et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Discovery of Notch Pathway-Related Genes for Predicting Prognosis and Tumor Microenvironment Status in Bladder Cancer

Sun

Xin

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: Notch signaling is a key regulator of immune cell differentiation and linked to autoimmune diseases, tumorigenesis and tumor-induced immunomodulation. An abnormally activated Notch signaling pathway contributes to almost all of the key features of cancer, including tumor angiogenesis, stemness, and epithelial-mesenchymal transition. Consequently, we investigated Notch pathway-related genes for developing prognostic marker and assessing immune status in bladder cancer.Methods: The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were utilized to analyze RNA-seq data for bladder cancer. Cluster subtypes were identified using the NMF algorithm. In order to establish a prognostic risk signature, the least absolute shrinkage and selection operator (Lasso) and Cox regression analysis was utilized. GSEA was carried out to investigate the molecular mechanisms. Immune cell infiltration levels in bladder cancer were calculated using the CIBERSORT algorithm. External clinical tissue samples were used to validate the expression levels of signature genes.Results: Based on the NMF algorithm, bladder cancer samples were divided into two cluster subtypes and displayed different survival outcome and immune microenvironment. A six-gene risk signature (DTX3L, CNTN1, ENO1, GATA3, MAGEA1, and SORBS2) was independent for prognosis and showed good stability. The infiltration of immune cells and clinical variables were significantly different among the risk groups of patients. Response to immunotherapy also differed between different risk groups. Furthermore, the mRNA expression levels of the signature genes were verified in tissue samples by qRT-PCR.Conclusion: We established a 6-gene signature associated with Notch pathway in bladder cancer to effectively predict prognosis and reflect immune microenvironment status.

show abstract

Section: Discussionmentioning

confidence: 99%

Discovery of Notch Pathway-Related Genes for Predicting Prognosis and Tumor Microenvironment Status in Bladder Cancer

Sun

Xin

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

show abstract

“…Consequently, all of these have hindered the diagnosis and treatment of bladder cancer to some extent. Given this, the rapid development of proteomics and peptidomics, especially in the identification of biomarkers, offers promising possibilities for bringing precision medicine to bladder cancer [281]. Currently, the main focus of bladder cancer research has been on the assessment of the urinary proteome and peptidome.…”

Section: Applications Of Plasma Proteomics/peptidomics In Covid‐19 An...mentioning

confidence: 99%

Clinical applications of plasma proteomics and peptidomics: Towards precision medicine

Huang

et al. 2022

Proteomics Clinical Apps

View full text Add to dashboard Cite

In the context of precision medicine, disease treatment requires individualized strategies based on the underlying molecular characteristics to overcome therapeutic challenges posed by heterogeneity. For this purpose, it is essential to develop new biomarkers to diagnose, stratify, or possibly prevent diseases. Plasma is an available source of biomarkers that greatly reflects the physiological and pathological conditions of the body. An increasing number of studies are focusing on proteins and peptides, including many involving the Human Proteome Project (HPP) of the Human Proteome Organization (HUPO), and proteomics and peptidomics techniques are emerging as critical tools for developing novel precision medicine preventative measures. Excitingly, the emerging plasma proteomics and peptidomics toolbox exhibits a huge potential for studying pathogenesis of diseases (e.g., COVID‐19 and cancer), identifying valuable biomarkers and improving clinical management. However, the enormous complexity and wide dynamic range of plasma proteins makes plasma proteome profiling challenging. Herein, we summarize the recent advances in plasma proteomics and peptidomics with a focus on their emerging roles in COVID‐19 and cancer research, aiming to emphasize the significance of plasma proteomics and peptidomics in clinical applications and precision medicine.

show abstract

“…It is expected that the molecular characterization of BC will reveal important information for stratification patients not only in terms of an early-stage cancer progression but also for predicting clinical outcomes and designing the most effective treatment, because not all tumors will respond in the same manner despite falling in the same classical clinical or anatomopathological staging and grading descriptors that were already depicted; thus, great efforts have been made and to date, nine molecular classification systems of MIBC and two of NMIBC have been proposed ( Figure 4 ) [ 39 ].…”

Section: Omics Sciences In the Molecular Classification Of Bladder Cancermentioning

confidence: 99%

“…The University of North Carolina (UNC): Luminal, and Basal. The Institut Curie (CIT-Curie 2014): Non-basal-like, and basal-like [ 39 ].…”

Section: Figurementioning

confidence: 99%

Proteomics as a Complementary Technique to Characterize Bladder Cancer

López-Cortés

Vázquez‐Estévez

Fernandez

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Bladder cancer (BC) is the most common tumor of the urinary tract and is conventionally classified as either non-muscle invasive or muscle invasive. In addition, histological variants exist, as organized by the WHO-2016 classification. However, innovations in next-generation sequencing have led to molecular classifications of BC. These innovations have also allowed for the tracing of major tumorigenic pathways and, therefore, are positioned as strong supporters of precision medicine. In parallel, immunohistochemistry is still the clinical reference to discriminate histological layers and to stage BC. Key contributions have been made to enlarge the panel of protein immunomarkers. Moreover, the analysis of proteins in liquid biopsy has also provided potential markers. Notwithstanding, their clinical adoption is still low, with very few approved tests. In this context, mass spectrometry-based proteomics has remained a step behind; hence, we aimed to develop them in the community. Herein, the authors introduce the epidemiology and the conventional classifications to review the molecular classification of BC, highlighting the contributions of proteomics. Then, the advances in mass spectrometry techniques focusing on maintaining the integrity of the biological structures are presented, a milestone for the emergence of histoproteomics. Within this field, the review then discusses selected proteins for the comprehension of the pathophysiological mechanisms of BC. Finally, because there is still insufficient knowledge, this review considers proteomics as an important source for the development of BC therapies.

show abstract

Blood-based protein biomarkers in bladder urothelial tumors

Cited by 12 publications

References 222 publications

Discovery of Notch Pathway-Related Genes for Predicting Prognosis and Tumor Microenvironment Status in Bladder Cancer

Discovery of Notch Pathway-Related Genes for Predicting Prognosis and Tumor Microenvironment Status in Bladder Cancer

Clinical applications of plasma proteomics and peptidomics: Towards precision medicine

Proteomics as a Complementary Technique to Characterize Bladder Cancer

Contact Info

Product

Resources

About